Skip to main content
GUTS logo

GUTS · Fractyl Health, Inc.

Track GUTS — free
$0.97 -0.11 (-9.92%)
Market Cap
$12.67M
Shares
13.26M
Volume · Nov 19 223.24K Avg daily vol (34 sessions) 804.78K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.96 Open$1.10 Day$0.95–1.12 52W close$0.81–28.44 Avg vol 30d884K Short int585K · 4.4% of shares · 1.0d Short vol38% Last earningsNov 12, 2026 DataFeb 2024–Nov 2026 Filing10-Q · Nov 12

Up next

Jan 28, 2027 Est · unconfirmed · in 10 wks

Latest documents

2026
Nov 12
Investor event
Remain One pivotal study met six-month endpoint, p-value 0.0023

Fractal's Remain One pivotal study met its six-month co-primary endpoint with a p-value of 0.0023, with Revita participants keeping about 80% of the weight they had lost on trisepatide. Fractal cut its workforce by approximately 45%, and it expects quarterly operating cash spending to fall to approximately $8 million by the end of the second quarter of 2027. Twelve-month data are due in the first quarter of 2027.

6 source passages
The study met its six-month co-primary endpoint with high statistical significance, p-value of 0.0023. Revita participants kept about 80% of the weight they had lost on a trisepatide, Now let's talk about how we have rebuilt Fractal around Revita. That meant reducing our workforce by approximately 45% and discontinuing internal development of our Rujua gene therapy program. we expect quarterly operating cash spending to be reduced by approximately 50% to approximately $8 million by the end of the second quarter of 2027. In the first quarter of 2027, we expect top-line 12-month data from the second co-primary endpoint. Open the document at this passage
Nov 12
Earnings call
Remain One endpoint met; cash runway reaches second quarter 2027

Fractal Health met Remain One’s six-month co-primary endpoint (p-value 0.0023) and plans Revita’s de novo submission for late 2026. A 45% workforce reduction targets approximately $8 million quarterly cash spending and runway into the second quarter of 2027.

4 source passages
The study met its six-month co-primary endpoint with high statistical significance, p-value of 0.0023. First is the submission of our de novo marketing application, which we plan to begin in the late fourth quarter of 2026. That meant reducing our workforce by approximately 45% and discontinuing internal development of our Rujua gene therapy program. we expect our quarterly operating cash spending to fall by approximately half to approximately $8 million by the end of the second quarter of 2027. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revita meets pivotal endpoint; 45% workforce cut amid funding uncertainty

Fractyl Health, Inc. said Revita met its six-month weight-retention endpoint (p=0.0023) and will reduce headcount by approximately 45%, while $31.5 million in cash funds operations only into the second quarter of 2027 and creates substantial going-concern doubt.

Net loss $14.15M Diluted EPS -$1.07
Read from the MD&A section
4 source passages
REMAIN-1 met its pre-specified six-month co-primary endpoint of weight loss retention, as patients treated with a single Revita procedure demonstrated a highly statistically significant reduction in weight regain compared to sham (p=0.0023). we will reduce our workforce by approximately 45% of our current headcount. our available cash and cash equivalents of $31.5 million as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2027 we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued. Open the document at this passage
Nov 12
Current report 8-K
Revita meets endpoint; workforce cut approximately 45%

Fractyl Health, Inc. said Revita met its endpoint, with approximately 80% weight-loss retention versus 67% for sham. A late Q4 2026 FDA De Novo submission is planned; cash runs into Q2 2027 amid a workforce cut of approximately 45%.

Financial results
5 source passages
REMAIN-1 Pivotal Cohort met its six-month co-primary endpoint with high statistical significance (p=0.0023); Revita® participants retained approximately 80% of GLP-1-induced weight loss versus 67% for sham Fractyl Health, Inc. The Company is reducing its workforce by approximately 45%, with the reduction expected to be completed during the fourth quarter of 2026. Late Q4 2026: Planned FDA De Novo submission for Revita in post-GLP-1 weight maintenance. Cash runway into Q2 2027, through planned De Novo submission and anticipated 12-month pivotal data; quarterly operating cash spending expected to be reduced by approximately 50%, to approximately $8 million, by the end of Q2 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$93,000
Trailing 12 months
Net income (TTM)
−$74.20M
Trailing 12 months
Revenue growth YoY
-57.1%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$31.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+145.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.4%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 15, 2026
Q2 FY26

TL;DR. Fractyl reported one-year randomized REMAIN-1 Midpoint and open-label REVEAL-1 data supporting durable post-GLP-1 weight maintenance with Revita, with pivotal REMAIN-1 6-month topline data on track for early Q4 2026 and a potential De Novo submission targeted for late Q4 2026. The company ended Q2 with $47.1 million in cash, guiding runway only into early 2027 and stating no plan to raise capital before pivotal data.

Bullish
  • + One-year randomized REMAIN-1 Midpoint data showed Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in the optimized complete-ablation population.
  • + Q2 2026 R&D expenses fell to $13.8 million from $21.2 million year over year, driving a $7.7 million improvement in Adjusted EBITDA loss to negative $16.3 million.
  • + Revita had zero device- or procedure-related serious adverse events through one year across both reported cohorts, supporting a favorable safety profile.
  • + Management stated the company is funded through definitive pivotal data and does not plan to raise capital before the readout, with $47.1 million in cash extending runway into early 2027.
Bearish
  • − Q2 2026 net loss was $25.5 million, with a $5.1 million higher non-cash loss from change in fair value of warrant liabilities worsening the bottom line versus the prior year.
  • − Management declined to provide Revita launch volume, pricing, or unit economics assumptions ahead of the September Investor Day, leaving commercial profitability and reimbursement specifics uncertain.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −86%
below
Price vs 50-day avg −71%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −91%
trailing
YTD return −96%
this year
Relative strength −85%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +15 funds added
Insider flow Accumulating
Net +$39.9K over 90 days · 0% sells
Short interest Rising
4.41% of shares out · ▲ +120.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
75 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −15%
Y/Y
Free cash flow $-90.9M
Quant / Vol
risk profile
Very High
Volatility 134%
annualized · 1-yr
Max drawdown −97%
past year
ATR 22.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 12, 2026
by the end of the second quarter of 2027
Quarterly operating cash spending $8M
Quarterly operating cash spending 50%
the fourth quarter
Severance and related charges $2M
the majority in the fourth quarter
Severance and related charges $2M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−86% Bearish
Price vs 50-day avg
−71% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $3 › 200d $7 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +15 funds added
Insider flow Accumulating
Net +$39.9K over 90 days · 0% sells
Short interest Rising
4.41% of shares out · ▲ +120.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
75 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $28
vs 200-day avg -86% vs 50-day avg -71%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GUTS
Fractyl Health, Inc.
this stock
$12.67M — -100.0% — 4.4%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
75
% held
39.4%
Net QoQ
-682.2K sh
Top holder
Catalio Capital Managemen…
Held Float
View
Held by Funds
Fund positions
12
View
Short & Settlement
Short Interest Rising
Shares short
585.1K
Days to cover
1.0d
Change
+319.6K sh
View
Short Volume
Short vol %
38%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
30.6K
Value
$30.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
62.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$39.9K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-141.0M
EPS diluted
$-22.32
View
Filings
SEC Filings
Latest
8-K/A
Filed
Nov 19, 2026
This year
34
View
Proposed Sales
Value
$226.1K
Shares
111.9K
Filed
Jan 30, 2025
View
Exempt Offerings
Offering
$20.1M
Filed
Jan 25, 2022
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Fractyl Health Reports Third Quar…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
GUTS +17.6% -15.5% -90.8% -2.2% -96.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +23.1% -9.2% -85.2% +3.1% -101.4%
Key facts CIK 1572616 CUSIP 35168W202 13F (30d) 87 filings 72 filers Visit website Investor relations